Hepatitis C

Patrons of 'Vampire Facial' Spa May Have Been Exposed to HIV

Patrons of 'Vampire Facial' Spa May Have Been Exposed to HIV

Inspection at the VIP Spa in Albuquerque detected practices that might spread HIV or hepatitis B and C.

HCV DAA Curative Therapy Associated With Liver Fibrosis Regression

HCV DAA Curative Therapy Associated With Liver Fibrosis Regression

Curing HCV infection with direct-acting antiretrovirals is associated with regression of liver fibrosis for most patients.

Factors Associated With Faster Time to Hepatitis C Treatment

Factors Associated With Faster Time to Hepatitis C Treatment

By

The researchers found a significant difference in mean time to direct-acting antiviral agent treatment among participants with public insurance payers compared with private insurance payers.

HCV Neuropsychiatric Symptoms Likely Linked to Virus' Effects on Brain Function

HCV Neuropsychiatric Symptoms Likely Linked to Virus' Effects on Brain Function

The neuropsychiatric symptoms associated with HCV infection are likely caused by the body's response to the virus' effects on brain function.

Real-World Efficacy of DAAs in African Americans With Chronic HCV GT-1 Infection

Real-World Efficacy of DAAs in African Americans With Chronic HCV GT-1 Infection

Direct-acting antivirals are safe and effective in African-American patients with chronic HCV.

Toward Integrated Care for Hepatitis C Infection and Addiction

Toward Integrated Care for Hepatitis C Infection and Addiction

There is an opportunity to improve HCV treatment rates for people who inject drugs by integrating DAA therapy into current models of community-based addiction.

Good Outcomes for HCV-Negative Recipients of HCV Kidneys

Good Outcomes for HCV-Negative Recipients of HCV Kidneys

All 20 recipients experienced HCV cure, good quality of life, excellent renal function.

Successful Screening and Referral for HIV, Hepatitis C in a Trauma Population

Successful Screening and Referral for HIV, Hepatitis C in a Trauma Population

Investigators added hepatitis C virus and HIV screening tests to standard trauma activation laboratory orders.

Coordinated Care Enhances Access to Hepatitis C Antiviral Treatment

Coordinated Care Enhances Access to Hepatitis C Antiviral Treatment

Coordinated treatment programs may improve treatment outcomes in patients with hepatitis C infection.

Project ECHO: Educational Support to Improve Hepatitis Care

Project ECHO: Educational Support to Improve Hepatitis Care

By

Project ECHO at Los Angeles Christian Health Center contributes to improved care of HCV in underserved populations.

DAA Therapy May Improve Select Cognitive Domains in HCV-Infected Patients

DAA Therapy May Improve Select Cognitive Domains in HCV-Infected Patients

Successful DAA therapy may lead to cognitive improvement in several domains in HCV-infected patients.

Hepatitis C-Exposed Infants Not Adequately Screened

Hepatitis C-Exposed Infants Not Adequately Screened

Low screening rate seen at same time as increase in hepatitis C virus prevalence among pregnant women

Healthcare Program Obtains 93% of Prior Authorization Approvals for HCV Medications

Healthcare Program Obtains 93% of Prior Authorization Approvals for HCV Medications

By

The Respectful & Equitable Access to Comprehensive Healthcare program obtained 93% of prior authorization approvals for hepatitis C medications.

Novel Medicaid Strategy Proposed to Increase Access to HCV Treatment

Novel Medicaid Strategy Proposed to Increase Access to HCV Treatment

A proposed novel Medicaid purchasing strategy is anticipated to increase access to medications that can eradicate hepatitis C virus infection without increasing costs at the state and federal levels.

Sofosbuvir Improves Renal Safety in Patients With Chronic Hepatitis C

Sofosbuvir Improves Renal Safety in Patients With Chronic Hepatitis C

Patients with mild, moderate renal impairment showed improvement in renal biomarkers over one year

Case Report: Nephrotic Syndrome and Chronic HCV in a 72-Year-Old Woman

Case Report: Nephrotic Syndrome and Chronic HCV in a 72-Year-Old Woman

By

A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.

Screening insufficient for newborns exposed to hepatitis C virus

In this retrospective study, only a fraction of infants receiving well-child care at the study institution were screened for hepatitis C, despite being born to mothers with a known history of hepatitis C virus infection.

Hepatitis C Screening Increasing Among Baby Boomers

Hepatitis C Screening Increasing Among Baby Boomers

Screening prevalence 11.5 to 12.8%; similar rate for cohort born from 1966 to 1985

Effectiveness of Shortened Treatment Regimen for Hepatitis C Assessed

Effectiveness of Shortened Treatment Regimen for Hepatitis C Assessed

In this large, real-world cohort of patients with chronic hepatitis C virus infection, equivalent sustained virologic response rates were found with both 8-week and 12-week treatment.

Direct-Acting Antivirals Improve Liver Transplant Survival

Direct-Acting Antivirals Improve Liver Transplant Survival

Direct-acting antivirals improved the survival of patients undergoing liver transplantation for HCV-related liver disease.

HCV treatment with direct antiviral agents improves carotid atherosclerosis

HCV treatment with direct antiviral agents improves carotid atherosclerosis

By

Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.

Prophylaxis may protect kidney recipients from HCV

Prophylaxis may protect kidney recipients from HCV

Prophylaxis safely, effectively prevents HCV transmittance in noninfected patients receiving kidney transplants from HCV-positive donors.

Drug combination effective for hepatitis C

Drug combination effective for hepatitis C

By

Elbasvir and grazoprevir, taken in combination for 12 weeks, successfully treated virologic response in patient with hepatitis C genotype 1b.

Once daily glecaprevir-pibrentasvir treats HCV genotype 1,3

Once daily glecaprevir-pibrentasvir treats HCV genotype 1,3

Once daily glecaprevir-pibrentasvir for 8 or 12 weeks successfully treated HCV genotype 1 and 3.

HCV treatment hinders liver fibrosis progression

HCV treatment hinders liver fibrosis progression

By

Patients with chronic HCV with a sustained virologic response were more likely to have a reduced progression of liver fibrosis.

Hepatitis increases mortality rates in HIV patients

Hepatitis increases mortality rates in HIV patients

By

Hepatitis B and hepatitis C may increase mortality risks in HIV patients.

Nurse practitioner treatment of hepatitis C in primary care

Nurse practitioner treatment of hepatitis C in primary care

By

Hepatitis C treatment improves outcomes and experiences for patient and provider.

Updated hepatitis C recommendations include kidney transplant, pregnant patients

Updated hepatitis C recommendations include kidney transplant, pregnant patients

By

The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America have added updates to the hepatitis C guidelines to include kidney transplant, pregnant, and pediatric patients.

Hepatocellular carcinoma risk unclear after hepatitis C treatment

Hepatocellular carcinoma risk unclear after hepatitis C treatment

The results show no evidence to support a hypothesis of differential impact of interferon and direct-acting antiviral-based cure on risk for HCC occurrence and recurrence.

Primary care providers and nurse practitioners can expand HCV treatment access

Primary care providers and nurse practitioners can expand HCV treatment access

Primary care providers and nurse practitioners achieve the same sustained virologic response rates as specialists.

Sign Up for Free e-newsletters